Biotech Values

[BTH]

Sadly, Stimuvax will probably show very good benefits in these "prespecified subsets" (as they called them) for which they should have designed a better Phase 3 initially, and not figured this stuff out now.

But, assume the subsets are great. They cant go to the FDA with those...I assume they would get NOWHERE. so, they run another Phase 3 in that selected population, and the readout is.....what, 2017? By then, PD-1 and its derivatives will probably have made NSCLC something managable like HIV/AIDS. ....rendering Stimuvax, worthless.